Sands et al. expand the therapeutic potential of anti-IL-12/IL-23 blockade in IBD, by demonstrating a clear clinical benefit of ustekinumab as induction and maintenance therapy for ulcerative colitis (UC). The UNIFI trial had a double-blind, placebo-control design and consisted of an 8-week induction and a 44-week randomized-withdrawal maintenance trial. Patients with active, moderate-to-severe UC (total Mayo score of 6-12 with endoscopic subscore of ≥2 via central reading) were recruited from 244 centers worldwide.